Market Intelligence, Clinical Progress, and High-Purity Reagents for Infectious Disease and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TMPRSS2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TMPRSS2 Recombinant Protein (Catalytic Domain / ECD) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native post-translational modifications. |
View TMPRSS2 Products |
| Gene Delivery | TMPRSS2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Ideal for viral entry and cell-based assays. |
View TMPRSS2 Products |
| Benchmark Ab | Anti-TMPRSS2 Recombinant Antibody Recombinant positive control for flow cytometry, IHC, and neutralization assays. |
View TMPRSS2 Products |
| Validator | TMPRSS2 siRNA Set For target knockdown verification and target validation assays. |
View TMPRSS2 Products |
| Related Target A | ACE2 Co-receptor for SARS-CoV-2 host cell entry; synergizes with TMPRSS2 activity. |
View ACE2 Products |
| Related Target B | Androgen Receptor (AR) Primary transcriptional regulator of TMPRSS2 expression in prostate cancer pathways. |
View AR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Maintaining Protease Enzymatic Activity | HEK293-expressed catalytic domain preserving native folding and auto-cleavage conformation. |
| Selectivity Screening Against Related Proteases | Homologue panel (including Matriptase, Furin, and Hepsin) strictly verified by mass spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and sequence-verified positive controls included. |
| False Positives in Small Molecule Screening | Validated siRNA sets included for specificity and functional knockdown checks in target cells. |
Live TMPRSS2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of TMPRSS2 spans two distinct clinical frontiers: oncology and infectious diseases. As a Type II Transmembrane Serine Protease (TTSP), TMPRSS2 is highly expressed in localized and metastatic prostate cancer, where its promoter drives the oncogenic TMPRSS2-ERG gene fusion. Concurrently, TMPRSS2 serves as the host cell protease responsible for priming the spike protein of SARS-CoV-2 and hemagglutinin of influenza viruses, making it a critical node for broad-spectrum antiviral intervention.
"The race for TMPRSS2 therapeutics is intensifying, with major players shifting focus from traditional systemically delivered serine protease inhibitors to highly selective small molecules and targeted degraders (PROTACs). As first-generation broad-spectrum inhibitors like Camostat and Nafamostat face limitations in bioavailability and selectivity, the next wave of R&D is targeting isoform-specific allosteric sites and localized pulmonary or prostatic delivery systems."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Ono Pharmaceutical, Academic Institutions | COVID-19, Influenza, Prostate Cancer | Enzymatic Inhibition Assays (Requires active recombinant catalytic domain protein with native glycosylation) |
| PROTACs / Degraders | Arvinas, University of Michigan | Prostate Cancer (CRPC) | Target Degradation Assays (Requires sequence-verified siRNA for validation and high-affinity antibodies) |
| Monoclonal Antibodies | Biotech Startups, Global Research Institutes | Viral Prevention, Cancer Metastasis | Conformational Epitope Binding (Requires high-purity ECD-Fc fusion proteins and stable cell lines via Lentivirus) |